RxDoctor Payments Data

Ricardo Cordido, MD

Cardiovascular Disease · Hamden, CTNPI 1003806456

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $105,884 of the $135,204 with a category attached, or 78.3%. 44 manufacturers reported payments, led by Johnson & Johnson at 50.9% of the total. Reporting peaked in 2019 at $58,948 and has fallen 95.8% since, to $2,497 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$135,204in general payments, 2019–2025

Across 807 payments — averaging $167.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$69K
  • Amgen$18K
  • Merck$15K
  • Novartis$15K
  • Medtronic$9K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $8K from 38 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$105,88478%
  • Travel & lodging$6,7275%
  • Food & beverage$21,97816%
  • Education$3150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,204 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$266,625
Medicare patients
639
Services billed
3,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban306$366,706
EliquisApixaban240$301,466
EntrestoSacubitril/Valsartan98$164,199
Repatha SureclickEvolocumab63$71,940
FarxigaDapagliflozin Propanediol39$56,297
BrilintaTicagrelor20$23,655
VerquvoVericiguat18$18,860
EdarbyclorAzilsartan Med/Chlorthalidone41$18,251
EdarbiAzilsartan Medoxomil27$15,415
LivaloPitavastatin Calcium20$14,874
VascepaIcosapent Ethyl31$13,654
Ranolazine ErRanolazine70$9,570
Nebivolol Hcl130$8,382
Rosuvastatin Calcium485$5,538
Olmesartan Medoxomil293$4,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$68,811$366,706306 claims
PfizerEliquis$528$301,466240 claims
NovartisEntresto$14,778$164,19998 claims
AstraZenecaFarxiga, Brilinta$959$79,95259 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$121$33,66668 claims
MerckVerquvo$15,330$18,86018 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$148$17,84831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Hamden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →